tetano
Editor, Senior Moderator
Front Immunol
. 2021 Sep 16;12:746447.
doi: 10.3389/fimmu.2021.746447. eCollection 2021.
Mosaic Hemagglutinin-Based Whole Inactivated Virus Vaccines Induce Broad Protection Against Influenza B Virus Challenge in Mice
Yonghong Liu[SUP] 1 [/SUP], Shirin Strohmeier[SUP] 1 [/SUP], Irene González-Domínguez[SUP] 1 [/SUP], Jessica Tan[SUP] 1 2 [/SUP], Viviana Simon[SUP] 1 2 3 4 [/SUP], Florian Krammer[SUP] 1 4 [/SUP], Adolfo García-Sastre[SUP] 1 2 3 4 5 [/SUP], Peter Palese[SUP] 1 2 [/SUP], Weina Sun[SUP] 1 [/SUP]
Affiliations
Abstract
Influenza viruses undergo antigenic changes in the immuno-dominant hemagglutinin (HA) head domain, necessitating annual re-formulation of and re-vaccination with seasonal influenza virus vaccines for continuing protection. We previously synthesized mosaic HA (mHA) proteins of influenza B viruses which redirect the immune response towards the immuno-subdominant conserved epitopes of the HA via sequential immunization. As ~90% of current influenza virus vaccines are manufactured using the inactivated virus platform, we generated and sequentially vaccinated mice with inactivated influenza B viruses displaying either the homologous (same B HA backbones) or the heterologous (different B HA backbones) mosaic HAs. Both approaches induced long-lasting and cross-protective antibody responses showing strong antibody-dependent cellular cytotoxicity (ADCC) activity. We believe the B virus mHA vaccine candidates represent a major step towards a universal influenza B virus vaccine.
Keywords: broad protection; immuno-subdominant epitopes; influenza B virus; universal influenza B vaccine; whole inactivated virus vaccine.
. 2021 Sep 16;12:746447.
doi: 10.3389/fimmu.2021.746447. eCollection 2021.
Mosaic Hemagglutinin-Based Whole Inactivated Virus Vaccines Induce Broad Protection Against Influenza B Virus Challenge in Mice
Yonghong Liu[SUP] 1 [/SUP], Shirin Strohmeier[SUP] 1 [/SUP], Irene González-Domínguez[SUP] 1 [/SUP], Jessica Tan[SUP] 1 2 [/SUP], Viviana Simon[SUP] 1 2 3 4 [/SUP], Florian Krammer[SUP] 1 4 [/SUP], Adolfo García-Sastre[SUP] 1 2 3 4 5 [/SUP], Peter Palese[SUP] 1 2 [/SUP], Weina Sun[SUP] 1 [/SUP]
Affiliations
- PMID: 34603333
- PMCID: PMC8481571
- DOI: 10.3389/fimmu.2021.746447
Abstract
Influenza viruses undergo antigenic changes in the immuno-dominant hemagglutinin (HA) head domain, necessitating annual re-formulation of and re-vaccination with seasonal influenza virus vaccines for continuing protection. We previously synthesized mosaic HA (mHA) proteins of influenza B viruses which redirect the immune response towards the immuno-subdominant conserved epitopes of the HA via sequential immunization. As ~90% of current influenza virus vaccines are manufactured using the inactivated virus platform, we generated and sequentially vaccinated mice with inactivated influenza B viruses displaying either the homologous (same B HA backbones) or the heterologous (different B HA backbones) mosaic HAs. Both approaches induced long-lasting and cross-protective antibody responses showing strong antibody-dependent cellular cytotoxicity (ADCC) activity. We believe the B virus mHA vaccine candidates represent a major step towards a universal influenza B virus vaccine.
Keywords: broad protection; immuno-subdominant epitopes; influenza B virus; universal influenza B vaccine; whole inactivated virus vaccine.